Co-Director, Vasculitis and Glomerulonephritis Center Massachusetts General Hospital Harvard Medical School Winchester, Massachusetts
Current vasculitis treatments (eg, glucocorticoids and alkylating agents) are associated with major adverse effects. Thankfully, recent research has shed more light on the pathogenesis of both small and large vessel vasculitis, leading to the development of novel biologic therapies that can take a more targeted approach. This session will explain how these new agents will hopefully result in more effective and less toxic treatment regimens for systemic vasculitis.
Learning Objectives:
Recognize the evidence supporting the standard of care for giant cell arteritis (GCA) and ANCA-associated vasculitis (AAV) including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
Summarize the pathophysiology of GCA, GPA an MPA identifying potential treatment targets
List several non-glucocorticoid immunosuppressants with recently demonstrated efficacy or under investigation for these conditions